Palatin Technologies, Inc.

NYSEAM:PTN Stock Report

Market Cap: US$28.2m

Palatin Technologies Past Earnings Performance

Past criteria checks 0/6

Palatin Technologies's earnings have been declining at an average annual rate of -42.5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 61.4% per year.

Key information

-42.5%

Earnings growth rate

-41.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-61.4%
Return on equityn/a
Net Margin-493.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Palatin Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSEAM:PTN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 237-35150
30 Sep 236-25150
30 Jun 235-28150
31 Mar 234-25170
31 Dec 223-26160
30 Sep 222-37160
30 Jun 221-36170
31 Mar 221-37160
31 Dec 211-35170
30 Sep 210-37190
30 Jun 210-34170
31 Mar 210-27150
31 Dec 200-27130
30 Sep 200-22100
30 Jun 200-22100
31 Mar 206037100
31 Dec 196037100
30 Sep 19603790
30 Jun 196036100
31 Mar 1921-590
31 Dec 18300100
30 Sep 1840890
30 Jun 18672590
31 Mar 18802680
31 Dec 178223100
30 Sep 177210100
30 Jun 1745-13100
31 Mar 1711-40100
31 Dec 160-4960
30 Sep 160-5260
30 Jun 160-5260
31 Mar 160-5060
31 Dec 150-4760
30 Sep 158-3160
30 Jun 1513-1860
31 Mar 1513-1050
31 Dec 1413-250
30 Sep 145-950
30 Jun 140-1450
31 Mar 140-14511
31 Dec 130-17511
30 Sep 130-15511
30 Jun 130-2150

Quality Earnings: PTN is currently unprofitable.

Growing Profit Margin: PTN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PTN is unprofitable, and losses have increased over the past 5 years at a rate of 42.5% per year.

Accelerating Growth: Unable to compare PTN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: PTN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.